Post-stroke epilepsy and antiepileptic drug use in men and women.
Loikas D, Linnér L, Sundström A, Wettermark B, von Euler M.
Basic & clinical pharmacology & toxicology. 2021; ():

Abstract

Evidence-based recommendations for choice of antiepileptic drug (AED) in post-stroke epilepsy (PSE) are lacking. The aim of this study was to describe the use and persistence of AEDs when initiating treatment in men and women with PSE. An observational study based on individual-level patient data from a regional health care register in Stockholm, Sweden, was conducted. Adults (>/=18 years) with a stroke diagnosis 2012-2016, a dispensed prescription of any AED within two years after the stroke, and with an epilepsy-related diagnosis were identified. Multinomial logistic regression and logistic regression was used to identify factors associated with choice of AED and discontinuation within 90 days, respectively. Of 9,652 men and 9,844 women with a stroke diagnosis, 287 men and 273 women had PSE and were dispensed AED. More than 60% of both men and women with PSE were treated with levetiracetam. Carbamazepine was the second most common drug followed by lamotrigine and valproic acid. There were significant differences in AED choice depending on for instance sex, age and renal impairment. Levetiracetam had the highest persistence in both men and women. Choice of AED, oral anticoagulant use and percutaneous endoscopic gastrostomy (PEG) showed an association with the persistence to therapy. We conclude that in both men and women with PSE, levetiracetam was the most used AED for initiation of treatment and also had the highest persistence. CI - This article is protected by copyright. All rights reserved.



P A G E S

Home
Journals
Keywords

P A R T N E R S

ScopeMed
BiblioMed
eJManager

Privacy Policy | citeindex.org © 2021